Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP) Talks about Drug Delivery Platform, Hill Street Beverage Deal and Human Clinical Trial Results

Investor Ideas #Potcasts #Cannabis News and Stocks on the Move: CEO of Lexaria Biosciences Corp (CSE: $LXX.C) (OTC: $LXRP)  Talks about Drug Delivery Platform,  Hill Street Beverage Deal and  Human Clinical Trial Results

Delta, Kelowna, BC –August 1, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca  release today’s edition of its series, Investorideas.com potcasts^CM - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

http://www.investorideas.com/Audio/Podcasts/2018/080118-CSELXX-CEO.mp3

Read this in full at http://www.investorideas.com/news/2018/cannabis/08011Potcasts-CSELXX-CEO.asp

Today’s podcast overview/transcript:

Good morning and welcome to another Investorideas.com potcast – looking at cannabis news, stocks to watch as well as insights from thought leaders and experts.

Today I will be talking with Chris Bunka the CEO of Lexaria Biosciences Corp. trading on the CSE as LXX and the OTC as LXRP.

Lexaria has developed a new disruptive drug delivery platform: DehydraTECH The Company’s patented technology changes the way Active Pharmaceutical Ingredients (“APIs”) enter the body orally by masking unwanted tastes, reducing the time of onset, avoiding first-pass liver metabolism and increasing bio-absorption by 5-10X.

Interview highlights:

Q:Investorideas.com

Can you explain in simple terms how the company’s delivery technology DehydraTECH™   works and some of the applications for the technology?

Chris Bunka:

“Our technology can be thought of as a dinner plate, we make a high-tech dinner plate. What you put on that is up to you. Our plate helps to pile that drug on and get it into your body more effectively. Our tech is based on some well-known bio chemistry which it’s the body’s propensity to absorb long chain fatty acids, similar to sunflower oil or avocado oil. We then “crazy glue” the long chain fatty acid to the side of the API. When you use our tech, you smell and taste the oleic acid, which has no taste and smell and masks the smell and taste of, in this case cannabinoids.”

Q: Investorideas.com

Your company has issued and pending patents in over 40 countries around the world.  That is impressive and somewhat unusual to find in a company of your size, so can you talk about your Intellectual property and licensing strategy? 

Chris Bunka:

“We have 49 patents pending in 43 countries around the world and 8 patents granted with regards to DehydraTECH. We’re a small company but we punch above our weight. We are perhaps the only company our size that has completed all in vitro, in vivo and human clinical studies. We recently released a human clinical study that was conducted in Europe using our turbo CBD hemp oil product. In that study we demonstrated that we are able to deliver much more cannabidiol into a human being and much more quickly. We compared the data to a previous study done by Mount Sinai Hospital with a cannabidiol provided by GW Pharmaceuticals (NASDAQ: GWPH)  . At the 30-minute mark, using our turbo CBD, we had over 900% more cannabidiol in blood then they did.”

Recent news:

Significant Bioavailability Results in Human Clinical Trial using Lexaria’s DehydraTECH (TM) Powered TurboCBD (TM) Capsules

https://ca.finance.yahoo.com/news/significant-bioavailability-results-human-clinical-101500729.html

Q: Investorideas.com

The company is forming four new wholly-owned subsidiaries, one each for the pharmaceutical, nicotine, hemp, and cannabis industries. Can you talk about this strategy and what it means for the bigger picture?

Chris Bunka:

 “We realize that companies in the pharmaceutical industry or the nicotine industry even today may not want to have any association to the cannabis industry, which was one of the reasons we wanted to build a fence around our different intellectual property assets. We think this also a good deal for our shareholders as it gives us the opportunity to take those subsidiaries down slightly different paths with separate financing which adds versatility to the company, minimizes shareholder dilution and helps us conduct business with a broader swath of fortune 500 and global companies.”

Q: Investorideas.com

On your website you say the legal cannabinoid consumer products space is expected to show Compounded Annual Growth Rate of more than 25% through 2021 in North America.  Do you see that increasing based on federal legalization here this fall and the push for federal legalization in the US? And  where do you see this industry ten years out ?

Chris Bunka:

 “The general answer is yes. I think the growth rates for cannabinoids edibles is going to be strongly double digit for the next years to come. I think as the market matures to embrace the “fat part’ of the demand curve, you’re going to see huge growth in consumer-friendly methods of ingesting cannabis. I don’t think most people realize we are in the first or second inning. You’re going to need the development of edibles legislation, international markets, international acceptance and societal acceptance. I wouldn’t be surprise to see double digit growth for a decade or more and in ten years I wouldn’t be surprise to see cannabis industry bigger then beer or wine.”

Recent news : Lexaria Bioscience and Hill Street Beverage Company Announce Definitive Agreement for Cannabis-Infused Beverages

https://ca.finance.yahoo.com/news/lexaria-bioscience-hill-street-beverage-102000015.html

If you would like to be a guest or sponsor this podcast contact Investorideas.com

Investor ideas reminds all listeners to read our disclaimers and disclosures on the Investorideas.com  website and this podcast is not an endorsement to buy products or services or securities. Investors are reminded all investment involves risk and possible loss of investment   

Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP)

Lexaria Bioscience Corp. has developed and out-licenses its disruptive delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. www.lexariabioscience.com

Sign up to get the news alerts including the daily podcast and transcript for Investor ideas podcasts    

Subscribe to the new cannabis podcast series:

http://www.investorideas.com/rss/feeds/Podcasts-Cannabis.xml

Or visit http://www.investorideas.com/Audio/Potcasts.asp

Or www.potcasts.ca

To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.

Investorideas.com podcasts are also available on iTunes,  Spotify, Google Play Music, Stitcher, Spreaker,  iHeartradio and Tunein.

Potcasts is now a certified word mark Trademark on the blockchain through Cognate, Inc. CM Certification-Registration Number: 10468217708

About Investorideas.com - News that Inspires Big Investing Ideas

Investorideas.com is a recognized news source publishing third party news and press releases plus we create original financial content. Learn about investing in stocks and  sector trends  from Investorideas.com with our news alerts , articles , podcasts and videos  talking about cannabis,  crypto,  technology including  AI and IoT , mining ,sports biotech, water, renewable energy and more . Investorideas.com original branded content includes the daily Crypto Corner and Podcast, Play by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News and Stocks on the Move podcast and column,  Cleantech and Climate Change Podcast and  the Stock Guru daily podcast on Support and Resistance Trading.

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp. Disclosure Lexaria Bioscience Corp. ( CSE: LXX) (OTC: LXRP) is a media sponsor of the podcast starting July 5 2018 more info http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp

Learn more about sponsoring this podcast or be a guest and our other branded content opportunities at Investorideas.com

Follow us on Social Media

https://www.facebook.com/Investorideaspotcasts/

https://twitter.com/MJInvestorIdeas

https://www.instagram.com/potcasts_investorideas/

Contact Investorideas.com

http://www.investorideas.com/About/Contact.asp

800-665-0411

Do you trade or invest in Marijuana / Hemp Stocks?  Check out our stock directory of publicly traded  CSE, TSX, TSXV, OTC, NASDAQ, NYSE, ASX Marijuana / Hemp Stocks

Join our Group on Linkedin  and talk about - Marijuana / Hemp Stocks - News and Trends in Green Investing

Investorideas.com - Investor Ideas Podcasts Now on #Spotify @Spotify ‏- #CryptoCorner, #Cannabis #Potcasts, Stock Guru Daily Podcast for Investing Ideas and Sector Trends

Investorideas.com - Investor Ideas Podcasts Now on #Spotify @Spotify ‏- #CryptoCorner, #Cannabis #Potcasts, Stock Guru Daily Podcast for Investing Ideas and Sector Trends

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - #Cannabisstocks: NanoSphere Health Sciences (CSE: NSHS) (OTC: NSHSF) Partners with Delta 9 for Canadian Expansion

Investorideas.com - #Cannabisstocks: NanoSphere Health Sciences (CSE: NSHS) (OTC: NSHSF) Partners with Delta 9 for Canadian Expansion

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - #Cannabisstocks: Aphria (TSX: $APH.TO and US OTC: $APHQF) Secures $25 Million Loan from WFCU Credit Union

Investorideas.com - #Cannabisstocks: Aphria (TSX: $APH.TO and US OTC: $APHQF) Secures $25 Million Loan from WFCU Credit Union

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - The Source Dispensaries Launch New Cannarillo Cannabis Cigars

Investorideas.com - The Source Dispensaries Launch New Cannarillo Cannabis Cigars

Get the latest Cannabis and Hemp stock news from www.investorideas.com

Investorideas.com - Scott Narins Joins Viridian Capital Advisors as Director of Business Development

Investorideas.com - Scott Narins Joins Viridian Capital Advisors as Director of Business Development

Lexaria Bioscience (OTCQX: $LXRP; CSE: $LXX.C) and Hill Street Beverage Company Announce Definitive Agreement for #Cannabis-Infused #Beverages

Lexaria Bioscience (OTCQX: $LXRP; CSE: $LXX.C) and Hill Street Beverage Company Announce Definitive Agreement for #Cannabis-Infused #Beverages

  

  

KELOWNA, BC and TORONTO, July 31, 2018  - Lexaria Bioscience Corp. (OTCQX: LXRP; CSE: LXX; the "Company" or "Lexaria"), a drug delivery platform innovator, and Hill Street Beverage Company Inc., (TSXV:BEER; "Hill Street") jointly announced that they have signed a Definitive Agreement to license Lexaria's DehydraTECHTM, on a semi-exclusive basis, for a term of five (5) years, to produce a line of cannabis-infused alcohol-free beverages for Canadian distribution, following regulatory approval. The Definitive Agreement is the conclusion of the process begun following the announcement of the non-binding letter of intent in April 2018. Terms of the Definitive Agreement were not disclosed.

  

Read this in full at http://www.investorideas.com/news/2018/cannabis/07313OTCQXLXRP.asp

US$56,250 (CDN$ 73,497), representing a portion of the compensation payable to Lexaria, shall be paid and satisfied in common shares in the capital of Hill Street, at a purchase price of CDN$0.175, for an aggregate of 419,982 common shares (the "Compensation Shares"). The issuance of the Compensation Shares is subject to regulatory approval, including without limitation, the approval of the TSX Venture Exchange.

Lexaria's beverage formulation adaptations use patented technology to act quickly, but without adding any taste or odour, thereby delivering predictable experiences that dissipate more quickly than many other cannabinoid edible products. Lexaria has already lab-tested Hill Street's alcohol-free red and white wines to formulate cannabinoid-fortified wines, and such tests show virtually zero cannabis taste or odour.

Hill Street CEO, Terry Donnelly, stated, "Our goal is to provide traditional beer and wine drinkers with great tasting products that use cannabis to mimic the onset and duration of effect that has historically come from alcohol, but without alcohol's toxicity and added calories. While the early versions of our wines infused with Lexaria's process have shown great promise, we are extremely excited about the progress Lexaria continues to make with their infusion technologies. Lexaria has already demonstrated its importance to our model as a key strategic partner in our business, and this agreement secures our future together. As Hill Street's progress into producing the world's finest alcohol-free and cannabis-infused beverages continues, Lexaria has demonstrated that they will continue to innovate and improve on their process. This will help to ensure Hill Street is always at the forefront of producing world-class wine, beer and other adult format beverages."

Chris Bunka, CEO of Lexaria stated, "Hill Street's award-winning and great-tasting wines and beers need an odourless and tasteless infusion process like our powerful DehydraTECHTM platform to ensure they will remain that way after the inclusion of cannabis. Our proven ability to render full spectrum cannabis and hemp oil into a water-soluble ingredient with no impact on the taste and smell of complex beverages like wine enables Hill Street to produce adult format beverages that will give consumers the recreational experience of cannabis, while enjoying tastes and experiences consistent with consuming traditional wine, beer and other adult format beverages."  

About Hill Street Beverage Company Inc. (TSXV:BEER)

Founded in 2008, Hill Street Beverage Company is the world's most award-winning company exclusively focused on alcohol-free beer, wines, and adult format beverages. Hill Street products include: Vin(Zero) wines, Vintense wines, Hill Street Craft Brewed Lager, and Designated Draft beer. Hill Street's award-winning products have won the Retail Council of Canada's Grand Prix, and numerous medals and accolades including three Gold, two Silver, and two Bronze Medals at the U.S. Open Beer Championships, and a prestigious Double Gold Medal at the San Francisco International Wine Challenge. As a result of the Royal Assent of Canada's Bill C-45, legislation to allow the sale of cannabis-infused beverages is to occur by October 17, 2019. Hill Street is currently applying for appropriate licenses to permit the production and sale of cannabis infused beverages in Canada, with the view of having infused products available for sale once the regulations permit. www.hillstreetbeverages.com

Follow Hill Street on Twitter https://twitter.com/hillstreetbevco

and on Facebook http://facebook.com/hillstreetbevco

About Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX)

Lexaria Bioscience Corp. licenses disruptive patented delivery technology that promotes healthier ingestion methods, lower overall dosing and higher effectiveness of lipophilic active molecules. Lexaria has multiple patents pending in over 40 countries around the world and has patents granted in the USA and in Australia for utilization of its DehydraTECHTM delivery technology. Lexaria's technology provides increases in intestinal absorption rates; more rapid delivery to the bloodstream; and important taste-masking benefits, for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules.

www.lexariabioscience.com

For regular updates, connect with Lexaria on Twitter https://twitter.com/lexariacorp

and on Facebook https://www.facebook.com/lexariabioscience/

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements which are not historical facts are forward-looking statements. Any references made by either company mentioned in this press release regarding forward-looking public statements concerning expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, including statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "project", "intend," "may," "could," "should," "will," and other similar expressions are forward-looking statements, including but not limited to: that any additional patent protection will be realized or that patent achievements will deliver material results. Such forward-looking statements are estimates reflecting either company's best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that other factors will not affect the accuracy of such forward-looking statements. Factors which could cause actual results to differ materially from those estimated by either company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process and other factors which may be identified from time to time in either company's public announcements and filings. There is no assurance that existing capital is sufficient for either company's needs or that either company will be able to raise additional capital. There is no assurance that either company will be capable of developing, marketing, licensing, or selling edible products containing cannabinoids, nicotine or any other active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of either company's postulated uses, benefits, or advantages for patented, patent-pending technology or unpatented processes will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA).  Neither company's products are intended to diagnose, treat, cure or prevent any disease.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE Hill Street Beverage Company Inc.

For further information: Press only: Terry Donnelly, Chairman and CEO, Hill Street Beverage Company Inc., terry@hillstreetbevco.com, (416) 543-4904; For investors: Gareth Tingling, Investor Relations, gareth@sophiccapital.com, (647) 797-0219; Lexaria Bioscience Corp., Alex Blanchard, Communications Manager, (778) 796-1897,

Investorideas.com potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts  is sponsored by Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer and disclosure info: http://www.investorideas.com/About/Disclaimer.asp. For disclosure purposes Lexaria Bioscience Corp is a paid client on Investorideas as a sponsor of the daily potcast  http://www.investorideas.com/About/News/Clientspecifics.asp

Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894. Global investors must adhere to regulations of each country.

Please read Investorideas.com privacy policy: http://www.investorideas.com/About/Private_Policy.asp